Want to see HK:2563 full AI Analyst Report?
2563 Stock Chart & Stats
HK$6.36
HK$0.54(3.44%)
At close: 4:00 PM EST
HK$6.36
HK$0.54(3.44%)
Day’s Range― - ―
52-Week RangeHK$2.40 - HK$9.63
Previous CloseN/A
Volume105.40K
Average Volume (3M)41.17K
Market Cap
HK$1.38B
Enterprise ValueHK$128.25M
Total Cash (Recent Filing)HK$565.53M
Total Debt (Recent Filing)HK$2.45M
Price to Earnings (P/E)―
Beta0.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding389,588,000
10 Day Avg. Volume43,120
30 Day Avg. Volume41,166
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)2.41
Price to Sales (P/S)48.10
P/FCF Ratio-10.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained product-level profitability (gross margins near 92%) indicates strong pricing power or low direct costs. This margin cushion helps absorb revenue volatility and supports long-term product economics, enabling viable unit economics if operating costs are reined in.
Very Low Financial LeverageExtremely low debt reduces bankruptcy and interest-rate risks and preserves financing optionality. A conservative capital structure gives management runway to restructure operations or raise equity without acute solvency pressure, an enduring advantage during prolonged cash burn.
Occasional Free Cash Flow ImprovementsIntermittent FCF improvement shows management can extract operational efficiencies and improve cash conversion in better periods. This demonstrates structural levers exist to reduce burn and suggests potential for sustained cash flow recovery if execution continues.
Bears Say
Sharp Revenue DeclineA steep, recent revenue drop signals weakening demand or lost commercial traction that can persist for multiple quarters. Declining top line undermines scale economics, stresses margins net of fixed costs, and lengthens the timeline to profitable operations absent a durable revenue rebound.
Persistent Deep UnprofitabilityChronic operating and net losses (net margins extremely negative) indicate structural cost-revenue imbalance. Persistent deficits erode equity, require repeated funding, and mean profitability depends on sustained, material improvements to either revenue or operating expense structure.
Sustained Negative Operating And Free Cash FlowOngoing cash burn constrains strategic flexibility and increases reliance on external funding despite low debt. Continued negative OCF/FCF can force dilutive financing or cost cuts, limiting investment in R&D/commercialization and threatening mid-term viability without corrective action.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H News
2563 FAQ
What was Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$2.40 and its highest was HK$9.63 in the past 12 months.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s market cap is HK$1.38B.
When is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Beijing Biostar Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Biostar Pharmaceuticals Co., Ltd. Class H pay dividends?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H does not currently pay dividends.
What is Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Biostar Pharmaceuticals Co., Ltd. Class H have?
Beijing Biostar Pharmaceuticals Co., Ltd. Class H has 389,588,000 shares outstanding.
What happened to Beijing Biostar Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beijing Biostar Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2563
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) Earnings & Revenues
Technical Analysis
Luye Pharma Group
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CANbridge Pharmaceuticals Inc.
―
Fangzhou Inc.
―
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
―